RxDoctor Payments Data

James Knapp, MD

Family Medicine · Turlock, CANPI 1033208145

Payments from drug & device makers

$1,191in general payments, 2019–2025

Across 74 payments — averaging $16.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$178
  • Lilly USA, LLC$162
  • Boehringer Ingelheim$128
  • Pfizer$110
  • Johnson & Johnson$96
  • Amgen$84
  • plus $434 from 15 others

What the payments were for

  • Food & beverage$1,14696%
  • Education$454%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,191 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$274,817
Medicare patients
766
Services billed
3,630

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin271$268,366
TrulicityDulaglutide109$133,572
XareltoRivaroxaban76$90,402
OzempicSemaglutide42$63,292
EliquisApixaban60$54,782
MounjaroTirzepatide40$50,731
RybelsusSemaglutide34$42,703
FarxigaDapagliflozin Propanediol29$36,497
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$31,911
Breo ElliptaFluticasone/Vilanterol73$28,354
JanuviaSitagliptin Phosphate15$23,373
JanumetSitagliptin Phos/Metformin Hcl19$20,805
Atorvastatin Calcium1,362$20,099
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$13,067
Repatha SureclickEvolocumab16$9,018

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat$128$281,433285 claims
Lilly USA, LLCTrulicity, Mounjaro$162$184,302149 claims
Novo NordiskOzempic, Rybelsus$41$105,99576 claims
Johnson & JohnsonXarelto$96$90,40276 claims
GSKTrelegy Ellipta, Breo Ellipta$36$60,265119 claims
PfizerEliquis$110$54,78260 claims
MerckJanuvia, Janumet$58$44,17834 claims
AstraZenecaFarxiga, Symbicort$178$42,28847 claims
Sanofi-aventis U.S. LLCLantus$11$3,89541 claims
AbbVieSynthroid$62$2,96937 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Turlock

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →